In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
Pricing Climate Impacting Commercial Considerations
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Estimated read time
1 min read
+ There are no comments
Add yours